key: cord-0814507-74d3y40e
authors: Strickland, Brian; Albala, Lorenzo; Coffey, El Centro; Carroll, Ryan W.; Zapol, Warren M.; Ichinose, Fumito; Berra, Lorenzo; Harris, N. Stuart
title: Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients
date: 2022-05-04
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2022.04.052
sha: 99cad0e1ef47ebef1548ff4a15adf7b87872ad5a
doc_id: 814507
cord_uid: 74d3y40e

Background Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator and mild bronchodilator that has been shown to improve systemic oxygenation, but has rarely been administered in the Emergency Department (ED). In addition to its favorable pulmonary vascular effects, in-vitro studies report that NO donors can inhibit replication of viruses, including SARS Coronavirus 2 (SARS-CoV-2). This study evaluated the administration of high-dose iNO by mask in spontaneously breathing emergency department (ED) patients with respiratory symptoms attributed to Coronavirus disease 2019 (COVID-19). Methods We designed a randomized clinical trial to determine whether 30 min of high dose iNO (250 ppm) could be safely and practically administered by emergency physicians in the ED to spontaneously-breathing patients with respiratory symptoms attributed to COVID-19. Our secondary goal was to learn if iNO could prevent the progression of mild COVID-19 to a more severe state. Findings We enrolled 47 ED patients with acute respiratory symptoms most likely due to COVID-19: 25 of 47 (53%) were randomized to the iNO treatment group; 22 of 47 (46%) to the control group (supportive care only). All patients tolerated the administration of high-dose iNO in the ED without significant complications or symptoms. Five patients receiving iNO (16%) experienced asymptomatic methemoglobinemia (MetHb) > 5%. Thirty-four of 47 (72%) subjects tested positive for SARS-CoV-2: 19 of 34 were randomized to the iNO treatment group and 15 of 34 subjects to the control group. Seven of 19 (38%) iNO patients returned to the ED, while 4 of 15 (27%) control patients did. One patient in each study arm was hospitalized: 5% in iNO treatment and 7% in controls. One patient was intubated in the iNO group. No patients in either group died. The differences between these groups were not significant. Conclusion A single dose of iNO at 250 ppm was practical and not associated with any significant adverse effects when administered in the ED by emergency physicians. Local disease control led to early study closure and prevented complete testing of COVID-19 safety and treatment outcomes measures.

bronchodilator that has been shown to improve systemic oxygenation, but has rarely been administered in the Emergency Department (ED). In addition to its favorable pulmonary vascular effects, in-vitro studies report that NO donors can inhibit replication of viruses, including SARS Coronavirus 2 (SARS-CoV-2). This study evaluated the administration of high-dose iNO by mask in spontaneously breathing emergency department (ED) patients with respiratory symptoms attributed to Coronavirus disease 2019 .

We designed a randomized clinical trial to determine whether 30 minutes of high dose iNO (250 ppm) could be safely and practically administered by emergency physicians in the ED to spontaneously-breathing patients with respiratory symptoms attributed to COVID-19. Our secondary goal was to learn if iNO could prevent the progression of mild COVID-19 to a more severe state.

We enrolled 47 ED patients with acute respiratory symptoms most likely due to COVID-19: 25 of 47 (53%) were randomized to the iNO treatment group; 22 of 47 (46%) to the control group (supportive care only). All patients tolerated the administration of high-dose iNO in the ED without significant complications or symptoms. Five patients receiving iNO (16%) experienced asymptomatic methemoglobinemia (MetHb) > 5%.

Thirty-four of 47 (72%) subjects tested positive for SARS-CoV-2: 19 of 34 were randomized to the iNO treatment group and 15 of 34 subjects to the control group. Seven of 19 (38%) iNO patients returned to the ED, while 4 of 15 (27%) control patients did. One patient in each study arm was hospitalized: 5% in iNO treatment and 7% in controls. One patient was intubated in the iNO group. No patients in either group died. The differences between these groups were not significant.

Nitric oxide (NO) is a selective pulmonary vasodilator which interacts with the pulmonary vasculature to induce smooth muscle relaxation [1, 2] . When given by inhalation (iNO), it dilates pulmonary vasculature, reduces ventilation/perfusion (V/Q) mismatch, and decreases both pulmonary arterial pressure and pulmonary vascular resistance [1] [2] [3] . Additionally, iNO causes bronchodilation and decreases platelet aggregation, preventing intra-pulmonary thrombosis [3, 4] .

For these reasons, iNO can improve oxygenation in mechanically ventilated patients [4] [5] [6] . Data also suggests that iNO has antiviral activity [7, 8] . A 2003 study of patients with SARS-CoV-1 infection reported that iNO improved oxygenation with benefits extending beyond the treatment period [9] . Additionally, in-vitro studies have demonstrated that the NO-donor compound Snitroso-N-acetylpenicillamine (SNAP) increased survival of in-vitro cells infected with SARS-CoV-1 and SARS-CoV-2 [8, 10, 11 ].

Prior studies have tested iNO concentrations ranging from 80-200 parts per million (ppm). A dose of 160 ppm has been found to be bactericidal and safe when administered under close observation [12, 13] . No studies investigating iNO use solely within the emergency department (ED) have been previously reported [14] [15] [16] .

In the early stages of the COVID-19 pandemic, when few therapeutic options were available, we used a face-mask device [17] [18] [19] to administer high-dose iNO (at 250 ppm) for 30 minutes as a one-time treatment for adult ED patients with COVID-19. This high concentration was chosen to maximize the known virucidal and vasoactive effects of iNO. Our goal was to establish the safety and practicality of administering this novel treatment within the ED to patients with acute respiratory symptoms of COVID-19, and to determine its effectiveness in decreasing disease progression.

We conducted a randomized clinical trial in patients presenting to the Massachusetts General Hospital (MGH) ED with respiratory symptoms most likely due to COVID-19. Subjects were spontaneously breathing adult patients who had been cleared for discharge to home by the attending emergency physician. All subjects were assayed by nasal swab for COVID-19 prior to J o u r n a l P r e -p r o o f Journal Pre-proof enrollment using polymerase chain reaction (PCR) testing. To accurately address treatment outcomes specific to COVID-19 progression, we designed an a priori subgroup analysis of subjects who eventually tested positive for COVID-19. This study was reviewed and approved by Partners Human Research Committees and registered at ClinicalTrials.gov. Patients provided informed consent prior to study procedures being performed.

This randomized clinical trial aimed to test practicality, safety, and efficacy of a single, novel high-dose administration of iNO by mask (250 ppm continuously for 30 minutes) in an ED patient population with respiratory symptoms most likely due to COVID-19.

The first aim of this study was to establish the safety of high-dose iNO in an ED patient population with COVID-19 related respiratory symptoms. Adverse events were defined as a primary endpoint of incidence of methemoglobin level (MetHb) > 5%, hypoxemia (SpO2<90%), and systemic hypotension (decrease in mean arterial pressure (MAP) > 50 mmHg).

The second aim was to establish that high-dose iNO could be practically and safely administered by emergency physicians in the ED, and could be well tolerated by ED patients with respiratory symptoms.

The final aim of this study was to determine whether early treatment with high-dose iNO could prevent the progression to a more severe disease state as measured by 1) return rates to the ED with COVID-19-related disease, 2) hospitalization, 3) intubation, and 4) 28-day mortality.

ED patients were eligible for enrollment if they were age 18 years old or older, had at least one respiratory sign or symptom of COVID-19 (cough, respiratory rate > 24 breaths/min, atypical chest pain, dyspnea, resting peripheral oxygen saturation (SpO2) < 97%, or chest radiograph consistent with COVID-19-related airspace disease.) Patients had fewer than 12 days of symptoms, positive or pending SARS-CoV-2 PCR tests, and clearance for discharge from the ED. Potential subjects were excluded if they were judged to have a > 50% likelihood of J o u r n a l P r e -p r o o f Journal Pre-proof alternative (non-COVID-19) etiology of their symptoms, had a tracheostomy, required oxygen therapy to maintain SpO2 > 94%, were pregnant, age > 90 years, had participated in other COVID-19 studies, or had a clinical contraindication to the use of iNO.

Following informed consent and enrollment, subjects were randomized to either the treatment group (iNO plus standard of care) [20, 21] or the control group (consisting of standard of care treatment) at a 1:1 ratio.

All subjects wore a snug-fitting mask attached to a non-rebreathing circuit capable of delivering continuous 250 ppm iNO through a reservoir bag and scavenging chamber to minimize nitrogen dioxide (NO 2 ) exposure [18] . NO balanced in nitrogen (Airgas; Radnor, Pennsylvania) was blended with medical air and oxygen to obtain the desired mixture based on prior in-vitro measurements. All subjects received 15 liters-per-minute (LPM) medical grade air and 2 LPM oxygen for a total of 30 minutes. Subjects in the iNO treatment group had 5 LPM of iNO [TABLE 2] added to this circuit to achieve a concentration of 250 ppm.

Vital signs (heart rate, respiratory rate, blood pressure, and SpO 2 ) and MetHb levels were continuously monitored throughout the duration of treatment. Abnormal oxygen saturation (SpO 2 < 90%), hypotension (a decrease in mean arterial pressure (MAP) > 50mmHg), were indications for immediate discontinuation of iNO treatment. If MetHb > 5%, the session was continued but iNO flow was decreased.

All subjects were observed for at least 5 minutes following administration of iNO or placebo, and discharged if their MetHb < 3% and downtrending, had SpO 2 > 94%, and had no new respiratory complaint.

In our study calculations, we calculated a need for a sample of a total of 236 patients. Patient background information was obtained from interviews and electronic health record review.

Historic and prospective data were collected and entered into a HIPPA-compliant, secure

In this study, we demonstrated safe and practical novel high-dose iNO administration within the ED (250 ppm for 30 minutes) in spontaneously breathing patients with respiratory symptoms of SARS-CoV-2 infection. While previous studies have described enrolling ED patients (with pulmonary embolism for eventual inpatient low-dose iNO administration (5-50 ppm) ), this is the first clinical trial reporting iNO administration within the ED [14] [15] [16] . Additionally, this is the first report of high-dose iNO (250ppm) in a clinical trial. [14] [15] [16] . This treatment was found to be safe and well-tolerated.

This study provides evidence that a single high dose of iNO at 250 ppm for 30 minutes can be safely administered by mask within the ED to patients with symptoms of acute respiratory illness. Patients receiving iNO had a low rate of significant methemoglobinemia, and MetHb levels rapidly normalized within minutes of discontinuing iNO. Patients did not experience significant symptoms, complications, or higher rate of repeat ED visits than those who maintained normal MetHb levels throughout.

Changes in disease prevalence led to premature study closure and prevented adequate testing of the hypothesis that a single high-dose iNO treatment can prevent respiratory decline of COVID-19 patients. Rates of return ED visits were slightly higher among the patients receiving iNO, however due to the small sample size, this was not a significant finding.

This study demonstrates that a single iNO treatment in this novel location (the ED) is well tolerated, can be practically and efficiently administered in the ED by emergency physicians, and poses little risk of hypoxemia, hypotension, or symptomatic methemoglobinemia even in the setting of acute respiratory disease and higher iNO concentrations. Timely access to effective therapy in the ED can be life-saving, and given our findings of safe and practical use of iNO in the ED, further studies to investigate its efficacy in other patients presenting to the ED with acute respiratory illness should be considered. Prior research has demonstrated the promise of iNO for the treatment of hospitalized patients with pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, lower respiratory tract infections, and high-altitude pulmonary edema [1] [2] [4] [5] 9, 22] . These patients could benefit greatly from the expansion of safe, timely, and effective ED treatment options. 

A marked decrease in subjects meeting entry criteria prevented this clinical trial from achieving its original treatment enrollment goal to test efficacy in reducing COVID-19 disease progression.

Our research group is investigating the timing of therapeutic iNO administration in populations of intubated ICU patients, spontaneously breathing hospitalized patients, and healthcare workers with a high risk of occupational SARS-CoV-2 exposure. Results of these studies have been independently reported [18, 19] .

This trial provides the first reported clinical experience reporting on iNO therapy given in the ED. Additionally, our novel high-dose administration (250 ppm for 30 minutes) was administered without adverse events by emergency physicians to patients with acute respiratory symptoms. Early study closure prevents meaningful comment on the efficacy of a single highdose of iNO in preventing progression of respiratory symptoms of early COVID-19 disease. J o u r n a l P r e -p r o o f 

Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by

Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults

Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

Gaseous nitric oxide reduces influenza infectivity in vitro

Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing

Mitigation of the replication of SARS-CoV-2 by Nitric Oxide in Vitro

Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected

Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study

Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure

Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial

Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism

Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism. Nitric Oxide

Ideation and assessment of a nitric oxide delivery system for spontaneously breathing subjects

Nitric Oxide Study Investigators. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia

High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19)

COVID-19 Treatment Guidance

Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema